Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC

Hereditary kidney cancer

(2010) W. Marston Linehan et al.   CANCER

Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism

(2010) Linda O'Flaherty et al.   HUMAN MOLECULAR GENETICS

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies

(2010) Mark Stein et al.   PROSTATE

UOK 262 cell line, fumarate hydratase deficient (FH−/FH−) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer

(2009) Youfeng Yang et al.   CANCER GENETICS AND CYTOGENETICS

Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1  Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species

(2009) S. Sudarshan et al.   MOLECULAR AND CELLULAR BIOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency

(2008) Jean-Pierre Bayley et al.   BMC Medical Genetics

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

(2007) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY